Sun Yat-sen Memorial Hospital,Sun Yat-sen University

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder	Not yet recruiting	Phase 2	2026-06-18		NCT06365008
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial	First-line Treatment; HER2-positive Metastatic Breast Cancer	Recruiting	Phase 3	2024-02-26		NCT06278870

Clinical trials